Peptide vaccines in immunocontraception

Valerie A Ferro, Emilio Mordini

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Vaccines have been used successfully to treat and eradicate infectious diseases; this has encouraged a major drive towards development of contraceptive vaccines (immunocontraception) as an additional method against rising human and animal populations. Despite three decades worth of research in this field, there are no licensed human contraceptive vaccines and less than ten for use in animals. The development of peptide antifertility vaccines has had a substantial impact on improving safety and specificity of immunogens, but has resulted in efficacy problems. Innovative strategies have been developed to overcome these problems.

LanguageEnglish
Pages83-89
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Volume6
Issue number1
Publication statusPublished - 29 Feb 2004

Fingerprint

Immunologic Contraception
Contraceptive Vaccines
Subunit Vaccines
Communicable Diseases
Vaccines
Safety
Research
Population

Keywords

  • animals
  • carrier proteins
  • contraception, immunologic

Cite this

@article{0b82f33d0bc3462685ba9905183fe92e,
title = "Peptide vaccines in immunocontraception",
abstract = "Vaccines have been used successfully to treat and eradicate infectious diseases; this has encouraged a major drive towards development of contraceptive vaccines (immunocontraception) as an additional method against rising human and animal populations. Despite three decades worth of research in this field, there are no licensed human contraceptive vaccines and less than ten for use in animals. The development of peptide antifertility vaccines has had a substantial impact on improving safety and specificity of immunogens, but has resulted in efficacy problems. Innovative strategies have been developed to overcome these problems.",
keywords = "animals, carrier proteins, contraception, immunologic",
author = "Ferro, {Valerie A} and Emilio Mordini",
year = "2004",
month = "2",
day = "29",
language = "English",
volume = "6",
pages = "83--89",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
number = "1",

}

Peptide vaccines in immunocontraception. / Ferro, Valerie A; Mordini, Emilio.

In: Current Opinion in Molecular Therapeutics, Vol. 6, No. 1, 29.02.2004, p. 83-89.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peptide vaccines in immunocontraception

AU - Ferro, Valerie A

AU - Mordini, Emilio

PY - 2004/2/29

Y1 - 2004/2/29

N2 - Vaccines have been used successfully to treat and eradicate infectious diseases; this has encouraged a major drive towards development of contraceptive vaccines (immunocontraception) as an additional method against rising human and animal populations. Despite three decades worth of research in this field, there are no licensed human contraceptive vaccines and less than ten for use in animals. The development of peptide antifertility vaccines has had a substantial impact on improving safety and specificity of immunogens, but has resulted in efficacy problems. Innovative strategies have been developed to overcome these problems.

AB - Vaccines have been used successfully to treat and eradicate infectious diseases; this has encouraged a major drive towards development of contraceptive vaccines (immunocontraception) as an additional method against rising human and animal populations. Despite three decades worth of research in this field, there are no licensed human contraceptive vaccines and less than ten for use in animals. The development of peptide antifertility vaccines has had a substantial impact on improving safety and specificity of immunogens, but has resulted in efficacy problems. Innovative strategies have been developed to overcome these problems.

KW - animals

KW - carrier proteins

KW - contraception, immunologic

UR - https://www.ncbi.nlm.nih.gov/labs/articles/15011785/

M3 - Article

VL - 6

SP - 83

EP - 89

JO - Current Opinion in Molecular Therapeutics

T2 - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 1

ER -